ClinicalTrials.gov
Cure8 trial brief
Why This Matters
A new Phase 3 trial is testing ponesimod, an oral S1P-modulator, for moderately to severely active ulcerative colitis — this could expand oral treatment options if later shown effective and safe.
The trial is actively recruiting and targets patients with prior inadequate response to approved UC therapies, so it may be relevant to people seeking additional options.
Who Should Pay Attention
Adults with moderately to severely active ulcerative colitis, patients who have had an inadequate response or intolerance to approved UC therapies, clinicians managing UC, and researchers interested in S1P-modulator therapies and UC clinical trial design.
Study Snapshot
Story typeClinical Reference
Trial phasePhase 3
Enrollment150 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
This is a registry entry for a Phase 3 trial still recruiting (per the record). It reports the study design, dosing strategy (oral daily with titration), main outcome (clinical remission at Week 16), and common inclusion/exclusion criteria — but it does not report any study results or safety/efficacy findings.
If you are considering participation, the record lists typical trial screening limits (age 18–75, recent endoscopic activity) and important exclusions such as prior S1P use and certain medical conditions.
How people use this: Patients and clinicians may use this record to identify an enrolling trial of an oral S1P-modulator for UC, and researchers may note the trial’s size, endpoints, and design.
For specific eligibility, risks, or to arrange participation, contact the listed investigative sites or the sponsor; the registry record is not a substitute for clinical consultation.
Keep In Mind
This is a ClinicalTrials.gov trial record (Phase 3, recruiting) and does not report outcomes or peer-reviewed results. The entry lists inclusion/exclusion criteria and trial procedures but not safety or efficacy data. Ponesimod belongs to the S1P-modulator class; prior exposure to this class is an exclusion in the study. For individual medical decisions, consult your clinician.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorVanda Pharmaceuticals
Trial IDNCT07686081
Study typeInterventional
Trial phasePhase 3
Enrollment150 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 18, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
This trial is testing duvakitug as a maintenance treatment for people with moderately to severely active ulcerative colitis who responded to an earlier study, which could expand treatment options if later shown to be...
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
A new Phase 3 trial is testing icotrokinra, an oral investigational drug, for induction and maintenance of remission in moderate–severe ulcerative colitis. Trials like this could expand treatment options if the drug...
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
Researchers are testing whether short-term dual therapy with vedolizumab plus tofacitinib can induce remission in people with moderate–severe UC who have failed prior TNF blockers. If effective and safe, this approach...